Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Jamba, Inc. (JMBA) A Good Stock To Buy?

Page 1 of 2

Looking for high-potential stocks? Just follow the big players within the hedge fund industry! This is not an ad, but let’s take a brief look at what statistics has to say about hedge funds’ stock picking abilities. The Standard and Poor’s 500 Index returned approximately 5.2% in the 12 months ending October 30, with more than 51% of the stocks in the index failing to beat the benchmark. Therefore, the odds that one will pin down a ‘winner’ by randomly picking a stock are less than the odds in a fair coin-tossing game. Conversely, hedge funds’ 30 preferred S&P 500 stocks (as of September 2014) generated a return of 9.5% during the same 12-month period, while 63% of these stock picks outperformed the broader market benchmark. Coincidence? It might happen to be so, but it is unlikely. Our research covering a 16-year period indicates that hedge funds’ stock picks generate superior risk-adjusted returns. That’s why we believe it is wise to check hedge fund activity before you invest your time or your savings on a stock like Jamba, Inc. (NASDAQ:JMBA).

Is Jamba, Inc. (NASDAQ:JMBA) a buy, sell, or hold? Money managers are reducing their bets on the stock. The number of long hedge fund positions was cut by 3 in recent months. JMBA was in 8 hedge funds’ portfolios at the end of September. There were 11 hedge funds in our database with JMBA holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as InVitae Corp (NYSE:NVTA), Garrison Capital Inc (NASDAQ:GARS), and Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) to gather more data points.

Follow Jamba Inc. (NASDAQ:JMBA)
Trade (NASDAQ:JMBA) Now!

If you’d ask most investors, hedge funds are seen as worthless, old investment tools of years past. While there are over 8000 funds trading today, our experts look at the leaders of this group, approximately 700 funds. It is estimated that this group of investors handle the lion’s share of the smart money’s total asset base, and by keeping an eye on their top picks, Insider Monkey has spotted many investment strategies that have historically surpassed the broader indices. Insider Monkey’s small-cap hedge fund strategy outstripped the S&P 500 index by 12 percentage points per year for a decade in their back tests.

Keeping this in mind, let’s take a gander at the fresh action encompassing Jamba, Inc. (NASDAQ:JMBA).

What does the smart money think about Jamba, Inc. (NASDAQ:JMBA)?

Heading into Q4, a total of 8 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -27% from the second quarter. With the smart money’s sentiment swirling, there exists a few notable hedge fund managers who were boosting their holdings substantially (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Glenn W. Welling’s Engaged Capital has the most valuable position in Jamba, Inc. (NASDAQ:JMBA), worth close to $24 million, accounting for 13.7% of its total 13F portfolio. On Engaged Capital’s heels is Indus Capital, led by David Kowitz and Sheldon Kasowitz, holding an $18.5 million position; 2.5% of its 13F portfolio is allocated to the stock. Remaining professional money managers with similar optimism encompass David Kowitz and Sheldon Kasowitz’s Indus Capital, Gregg J. Powers’s Private Capital Management and Gregory Bylinsky and Jefferson Gramm’s Bandera Partners.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!